Sean Anthony Eddy Shares of Cerus ( NASDAQ: CERS ) fell 10% in post-market trading after the company said European regulators declined to approve its Intercept Red Blood Cell product due to insufficient data. Cerus ( CERS ) said it is assessing strategies for preparing a new, enhanced.
Back to Health Page
